Proteins and Peptides

11 Jul 2017 Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
11 Jul 2017 BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
11 Jul 2017 Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
06 Jul 2017 Potential Breakthrough Therapy for Cancer Based on Pepscan's CLIPS Technology
03 Jul 2017 Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
02 Jul 2017 BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
02 Jul 2017 Ipsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport® (abobotulinumtoxinA) in the United States
30 Jun 2017 Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
30 Jun 2017 Cytovation Announces Private Fundraising Round of NOK 20m to Progress CyPep-1 to Phase 1 Clinical Study
30 Jun 2017 ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017
30 Jun 2017 Apellis Pharmaceuticals Announces Positive Data from APL-2 Studies Showing Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH
30 Jun 2017 Windtree Announces Top-Line Results from AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants
27 Jun 2017 Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH
27 Jun 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
26 Jun 2017 AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
25 Jun 2017 Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
23 Jun 2017 Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar
23 Jun 2017 FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease
22 Jun 2017 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
22 Jun 2017 Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes
21 Jun 2017 Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
19 Jun 2017 Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
17 Jun 2017 Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
15 Jun 2017 Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial
13 Jun 2017 New LEADER analysis shows Victoza® reduces cardiovascular risk in people with type 2 diabetes regardless of severe hypoglycaemia events

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing